Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.

For patients with low heterogeneity, the benefit from endocrine therapy did not reach statistical significance (Full model: HR = 0.67; 95% CI, 0.42–1.09, Crude model: HR = 0.69; 95% CI, 0.44–1.10). 3.3 Time‐varying multivariable analysis of PR intra‐tumor heterogeneity Time‐varying analysis was conducted to evaluate whether the hazard ratio of distant recurrence for patients with high PR intra‐tumor heterogeneity, compared to those with low heterogeneity, varied over the 20‐year follow‐up period.

also in 111,027 other papers